| The role of CD95 and CD95 ligand in cancer ME Peter, A Hadji, AE Murmann, S Brockway, W Putzbach, A Pattanayak, ... Cell death & differentiation 22 (4), 549-559, 2015 | 424 | 2015 |
| TLR4 mutation reduces microglial activation, increases Aβ deposits and exacerbates cognitive deficits in a mouse model of Alzheimer's disease M Song, JJ Jin, JE Lim, J Kou, A Pattanayak, JA Rehman, HD Kim, ... Journal of neuroinflammation 8, 1-14, 2011 | 293 | 2011 |
| Death induced by CD95 or CD95 ligand elimination A Hadji, P Ceppi, AE Murmann, S Brockway, A Pattanayak, B Bhinder, ... Cell reports 7 (1), 208-222, 2014 | 94 | 2014 |
| MyD88 deficiency ameliorates β-amyloidosis in an animal model of Alzheimer's disease JE Lim, J Kou, M Song, A Pattanayak, J Jin, R Lalonde, K Fukuchi The American journal of pathology 179 (3), 1095-1103, 2011 | 94 | 2011 |
| CD95 and CD95L promote and protect cancer stem cells P Ceppi, A Hadji, FJ Kohlhapp, A Pattanayak, A Hau, X Liu, H Liu, ... Nature communications 5 (1), 5238, 2014 | 92 | 2014 |
| Removal of Arsenic from Drinking Water by Chemical Precipitation–A Modeling and Simulation Study of the Physical‐Chemical Processes P Pal, SZ Ahammad, A Pattanayak, P Bhattacharya Water environment research 79 (4), 357-366, 2007 | 58 | 2007 |
| Anti-amyloid-β single-chain antibody brain delivery via AAV reduces amyloid load but may increase cerebral hemorrhages in an Alzheimer's disease mouse model J Kou, HD Kim, A Pattanayak, M Song, JE Lim, H Taguchi, S Paul, ... Journal of Alzheimer's Disease 27 (1), 23-38, 2011 | 42 | 2011 |
| The effects of MyD88 deficiency on exploratory activity, anxiety, motor coordination, and spatial learning in C57BL/6 and APPswe/PS1dE9 mice JE Lim, M Song, J Jin, J Kou, A Pattanayak, R Lalonde, K Fukuchi Behavioural brain research 227 (1), 36-42, 2012 | 38 | 2012 |
| Precision therapeutic targeting of human cancer cell motility L Xu, R Gordon, R Farmer, A Pattanayak, A Binkowski, X Huang, M Avram, ... Nature communications 9 (1), 2454, 2018 | 36 | 2018 |
| Catalytic immunoglobulin gene delivery in a mouse model of Alzheimer’s disease: prophylactic and therapeutic applications J Kou, J Yang, JE Lim, A Pattanayak, M Song, S Planque, S Paul, ... Molecular neurobiology 51, 43-56, 2015 | 25 | 2015 |
| Muscle-directed anti-Aβ single-chain antibody delivery via AAV1 reduces cerebral Aβ load in an Alzheimer’s disease mouse model J Yang, A Pattanayak, M Song, J Kou, H Taguchi, S Paul, S Ponnazhagan, ... Journal of molecular neuroscience 49, 277-288, 2013 | 24 | 2013 |
| Genistein treatment duration effects biomarkers of cell motility in human prostate H Zhang, R Gordon, W Li, X Yang, A Pattanayak, G Fowler, L Zhang, ... PloS one 14 (3), e0214078, 2019 | 23 | 2019 |
| Production of meso-and giga-porous zirconia particles—An improved multi-step particle aggregation process A Pattanayak, A Subramanian Powder Technology 192 (3), 359-366, 2009 | 21 | 2009 |
| Combined treatment of Aβ immunization with statin in a mouse model of Alzheimer's disease J Kou, M Song, A Pattanayak, JE Lim, J Yang, D Cao, L Li, K Fukuchi Journal of Neuroimmunology 244 (1-2), 70-83, 2012 | 16 | 2012 |
| Impact of porogens on the pore characteristics of zirconia particles made by polymer‐induced colloid aggregation A Pattanayak, A Subramanian International Journal of Applied Ceramic Technology 8 (1), 94-111, 2011 | 11 | 2011 |
| A multifunctional therapy approach for cancer: Targeting Raf1-Mediated inhibition of cell motility, growth, and interaction with the microenvironment L Zhang, A Pattanayak, W Li, HK Ko, G Fowler, R Gordon, R Bergan Molecular cancer therapeutics 19 (1), 39-51, 2020 | 5 | 2020 |
| Effect of porogens on particle morphology, pore size, pore geometry and pore architecture of zirconia supports A Pattanayak University of Nebraska--Lincoln, 2007 | 2 | 2007 |
| Dual acting bone defender agents inhibit prostate cancer-mediated bone destruction F Qiao, R Gordon, A Pattanayak, K O’Neill, N Chaika, W Chen, ... Cancer Research 83 (7_Supplement), 570-570, 2023 | | 2023 |
| Bisphosphonate-linked compounds R Bergan, R Gordon, A Pattanayak US Patent App. 17/428,951, 2022 | | 2022 |
| A new class of precision therapeutics that inhibit prostate cancer mediated bone destruction RR Gordon, A Pattanayak, W Li, R Bergan Cancer Research 81 (13_Supplement), 46-46, 2021 | | 2021 |
Paolo CeppiAssociate Professor, University of Southern Denmark在 bmb.sdu.dk 的电子邮件经过验证
